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Abstract
To investigate whether protein import is defective in mitochondrial disease, we compared the rate of import and the
expression of protein import machinery components in skin fibroblasts from control subjects and a patient with multiple
mitochondrial disease (MMD). The patient exhibited a 35% decrease in cytochrome c oxidase activity and a 59% decrease in
cellular oxygen consumption compared to control. Western blot analyses revealed that patient levels of MDH, mtHSP70,
HSP60, and Tom20 protein were 57%, 20%, 75% and 100% of control cells, respectively. MDH and Tom20 mRNA levels
were not different from control levels, whereas mtHSP70 mRNA were 50% greater than control. Radiolabeled MDH was
imported into mitochondria with equal efficiency between patient (44% of total synthesized) and control (43%) cells,
although the total MDH synthesized in patient cells was reduced by about 40%. The unaffected levels of mRNA and post-
translational import into mitochondria, combined with reduced protein levels of MDH, mtHSP70, and HSP60 suggest a
translational defect in this patient with MMD. This was verified by the 50% reduction in overall cellular protein synthesis in
the patient compared to control. Further, the similar import rates between patient and control cells suggest an important role
for Tom20, but a lesser role for mtHSP70 in regulating protein import into mitochondria. ß 2001 Elsevier Science B.V. All
rights reserved.
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1. Introduction
As most of the energy required for cellular func-
tions is derived from oxidative phosphorylation, mi-
tochondrial defects which result in a decreased sup-
ply of ATP often lead to disease [1,2]. The reported
minimum prevalence of mtDNA defects has ranged
from 12.5 to 16.3 per 100 000, whereas the prevalence
of other muscular disorders such as Duchenne and
Becker muscular dystrophies has been reported as 2.9
and 1.9 per 100 000, respectively [3^5]. These data
suggest that mitochondrial defects represent a signif-
icant proportion of muscular disorders.
The heterogeneity of mitochondrial disease is a
product of the complex genetics required for mito-
chondrial maintenance and biogenesis, as well as the
polyploidic nature of mitochondrial DNA (mtDNA).
MtDNA mutations can a¡ect the function or expres-
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sion of the thirteen constituent protein subunits, all
of which are essential components of respiratory
chain enzymes [6]. Point mutations in mitochondrial
genes encoding mRNA, tRNA, and rRNA have all
been associated with a vast array of mitochondrial
diseases, including Leber’s hereditary optic neuropa-
thy (LHON [7]), myoclonic epilepsy and ragged red
¢bers (MERRF [8]), and diabetes mellitus [9]. Like-
wise, large deletions of mtDNA, which encompass
several mtDNA genes, are the cause of myopathic
syndromes such as chronic progressive external oph-
thalmoplegia (CPEO; [10]). The severity of the dis-
eases is dependent on the amount of mutated
mtDNA in speci¢c tissues [11,12].
Nuclear mutations have also been identi¢ed as
causes of mitochondrial disease. This is because a
large majority of mitochondrial proteins are nu-
clear-encoded, translated in the cytosol, imported
into the organelle and assembled into the holoen-
zyme to impart function. For example, nuclear mu-
tations have been identi¢ed in the £avoprotein sub-
unit of complex II in Leigh’s syndrome patients [13].
In addition, mutations have been found in subunits
of other enzymes of aerobic metabolism such as the
E1K subunit of pyruvate dehydrogenase in myo-
pathic patients with decreased PDH activity [14].
More recently, the defective DDP1 protein of the
Mohr^Tranebjaerg Syndrome was found to be ho-
mologous to Tim8p family of proteins located in
the mitochondrial intermembrane space of Saccharo-
myces cerevisiae [15]. These polypeptides function to
transport and insert preproteins into the inner mem-
brane. This strongly suggests that defects in the mi-
tochondrial import machinery can, in some cases, be
directly involved in the etiology of mitochondrial dis-
ease. In support of this, decreased expression of
HSP60, a protein involved in the ¢nal refolding steps
of the import pathway, has been found in patients
with encephalomyopathy, resulting from its de-
creased synthesis and ine⁄cient mitochondrial im-
port of the protein [16]. Furthermore, it appears
that protein import defects may a¡ect the integrity
of mtDNA, since yeast studies have shown that mu-
tations in the 70 kDa protein translocase of the outer
membrane (Tom70) resulted in large deletions of
mtDNA [17]. Therefore, protein import defects could
represent a previously unforeseen primary cause of
mitochondrial disease in humans.
Thus, the purpose of this study was to determine
whether defects in mitochondrial protein import
could account for reduced mitochondrial function
in a patient diagnosed with multiple mitochondrial
disease. In contrast to our hypothesis, our results
indicate that events upstream of the mitochondrial
protein import step, particularly at the level of pro-
tein synthesis, appear to limit the expression of ma-
trix-localized proteins.
2. Materials and methods
2.1. Cell culture
Human skin ¢broblasts from a patient diagnosed
with multiple mitochondrial disease and two control
subjects were grown in K-MEM supplemented with
100 Wg/ml uridine, 10% FBS and 1% penicillin at
37‡C and 5% CO2. As patient ¢broblasts grew
more slowly than control cells, in order to reach
con£uence concurrently the patient cells were plated
at approximately 50% greater density. C2C12 myo-
blasts were grown to con£uence in DMEM supple-
mented with 10% FBS and 1% penicillin at 37‡C and
5% CO2.
2.2. Cytochrome c oxidase (COX) assay
Fibroblasts were washed and scraped with ice-cold
DPBS (Sigma, St. Louis, MO, USA). After centrifu-
gation, pellets were resuspended in 100 mM Na^K^
PO4/2 mM EDTA (pH 7.2), sonicated on ice (4U10
s), frozen in liquid N2 and subsequently thawed.
Samples were then centrifuged for 5 min at 4‡C
and the supernates were used to measure COX activ-
ity.
2.3. Protein extracts and Western blots
The cells were washed with PBS, and scraped with
2U Laemmli bu¡er (62.5 mM Tris (pH 6.8), 20%
glycerol, 2% SDS, 5% L-mercaptoethanol, 1 mM
PMSF). Equal amounts of total protein (40 Wg)
were separated on 12% (HSP60, mtHSP70 and
MDH) or 15% (Tom20, Tfam) polyacrylamide gels.
Samples were transferred from the gels to nitrocellu-
lose membranes, which were subsequently blocked
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for 1 h in 5% skimmed milk and 1.25% horse serum.
The blots were then incubated with primary antibody
overnight at 4‡C, and subsequently for 1.5 h at room
temperature with secondary antibody conjugated to
a horseradish peroxidase enzyme (1 MDH 1:1000 2
anti-rabbit 1:2000; 1 Tom20 1:1000 2 anti-rabbit
1:2000; 1 HSP60 1:1000 2 anti-mouse 1:1000; 1
mtHSP70 1:1000 2 anti-mouse 1:1000; 1 Tfam
1:1000 2 anti-rabbit 1:1000). The blots were visual-
ized using the ECL detection system (Amersham
Pharmacia Biotech, Mississauga, Canada).
2.4. In vivo 35S-radiolabeling and immunoprecipitation
Cells were starved for 1.5 h in methionine-free me-
dia and then incubated for 6 h with 300 WCi of
[35S]methionine per 150-mm plate. The plates were
scraped with TENT bu¡er (50 mM Tris^HCl (pH
7.4), 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-
100) containing 200 Wg/ml PMSF. The resulting ex-
tracts were incubated with MDH antibody (7 Wl) for
1 h at 4‡C, then with protein A Sepharose beads (10
mg) for 1 h at 4‡C. The beads were washed with
TENT bu¡er, resuspended in 2U Laemmli bu¡er
and incubated for 5 min at 95‡C. After a brief
spin, sodium dodecyl sulfate^polyacrylamide gel elec-
trophoresis (SDS^PAGE) was used to separate the
proteins in the immunoprecipitate. Radioactive pro-
teins were visualized using electronic autoradiogra-
phy.
2.5. Isolation of mRNA and slot blots
After washing and scraping in ice-cold DPBS, cells
were collected by centrifugation and resuspended in
Trizol reagent (Gibco). Following a chloroform/iso-
amylalcohol extraction, RNA was precipitated in iso-
propanol for 10 min at room temperature. After a
10-min centrifugation, the RNA pellet was washed in
75% ethanol, dried and resuspended in water. Con-
centrations were estimated by measuring the absor-
bance at 260 nm. Total RNA was applied to a nylon
membrane using a slot blot apparatus and ¢xed us-
ing a UV transilluminator. The blots were then pre-
hybridized for 2 h and probed with K32P-labeled
cDNA, encoding MDH, Tom20, mtHSP70 or 18S
rRNA overnight at 42‡C, as done previously [22].
The membranes were then washed three times for
30 min at 50‡C in 2U SSC/0.1% SDS, followed by
two 15-min washes at 50‡C and 55‡C in 0.1U SSC/
0.1% SDS. Radioactivity was quanti¢ed using elec-
tronic autoradiography.
2.6. Total protein synthesis
Extracts (10 Wl) prepared from the 35S-radiolabel-
ing procedure were spotted onto individual 3-mm
Whatmann ¢lter papers and allowed to dry. To pre-
cipitate the proteins, the ¢lter papers were placed in
ice cold 5% TCA containing 5 mM methionine. Sub-
sequently, proteins were ¢xed by boiling, and free
radioactivity was removed with an ice-cold wash of
the same solution. Incorporated radioactivity was
measured with a scintillation counter and expressed
per Wg of protein assessed using the Bradford total
protein assay.
2.7. Isolation of DNA and Southern blot
After washing and scraping in ice-cold DPBS, cells
were collected by centrifugation, resuspended in di-
gestion bu¡er (100 mM NaCl, 10 mM Tris^HCl (pH
8.0), 25 mM EDTA (pH 8.0), 0.5% SDS, 0.1 mg/ml
proteinase K), and incubated overnight at 50‡C. Fol-
lowing a phenol/chloroform extraction, nucleic acids
were precipitated in ethanol containing 7.5 M ammo-
nium acetate and centrifuged at 8000Ug for 10 min.
The resulting pellet was resuspended in TE (pH 8.0)
and residual RNA was eliminated by the addition of
DNase-free RNase. After a second phenol/chloro-
form extraction and ethanol precipitation, total cel-
lular DNA was resuspended in TE bu¡er. Equal
amounts of DNA were then digested with EcoRI
and XbaI overnight, and electrophoresed on 1% aga-
rose gels. The gel was then washed for 10 min in 0.2
N HCl, followed by two 30-min washes in denatur-
ation bu¡er (0.4 N NaOH, 0.6 M NaCl) and a sub-
sequent 30-min wash in neutralization bu¡er (0.5 M
Tris^HCl (pH 7.5), 1.5 M NaCl). DNA was trans-
ferred overnight using capillary blotting in 10U SSC
to a nylon membrane. The DNA was ¢xed to the
nylon using a UV transilluminator, and the blot
was pre-hybridized for 3 h and then probed with
K32P-labeled cytochrome c oxidase subunit II (COX-
II) cDNA overnight at 42‡C. The membrane was
successively washed in 2U SSC/0.1% SDS for 5
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and 15 min at room temperature, followed by two
15-min washes in 0.5U SSC/0.1% SDS and 0.1U
SSC/0.1% SDS at room temperature, and two subse-
quent 30-min washes with 0.1U SSC/1.0% SDS at
42‡C and 50‡C. Radioactivity was visualized using
electronic autoradiography.
2.8. Oxygen consumption
To measure oxygen consumption, cells were ¢rst
trypsinized, washed and resuspended in pre-warmed
DPBS. The samples, without additional reagents,
were then placed in magnetically stirred sample
chambers containing a Clarke oxygen electrode. All
measurements were normalized to total protein con-
tent.
3. Results
Western blots revealed that the expression of the
mitochondrial matrix enzyme malate dehydrogenase
(MDH) was reduced to 57% of control levels in pa-
tient ¢broblasts (Fig. 1A). To determine whether this
was due to decreased import of MDH into mito-
chondria, ¢broblasts were in vivo-labeled with
[35S]methionine, and MDH was subsequently immu-
noprecipitated from total cellular proteins using a
polyclonal antibody. Mouse C2C12 muscle cells
were used for comparison. While C2C12 cells re-
quired only 1 h of labeling (Fig. 1B), both control
and patient cells required a minimum of 6 h to ob-
tain a quanti¢able signal. Results of the immunopre-
cipitation revealed that the synthesis of total MDH
(i.e., precursor and mature forms) was reduced by
38% in the patient ¢broblasts. Despite this, the per-
centage of imported MDH was not di¡erent between
patient (44%) and control cells (43%; Fig. 1B).
In order to relate mitochondrial import to func-
tional proteins of the import process, the steady state
expression of key import machinery components was
measured. Western blot analyses revealed that total
(precursor and mature) HSP60 and mtHSP70 in pa-
tient cells were decreased to 75% and 20% of control
levels, respectively (Fig. 2). In contrast, the expres-
sion of Tom20 was not di¡erent between control and
patient ¢broblasts. In addition, the import of HSP60,
measured as steady state levels of the mature form of
HSP60 as a fraction of the total amount of HSP60,
was not signi¢cantly di¡erent from control cells.
To evaluate whether di¡erences in protein levels in
patient cells were a result of changes in mRNA ex-
pression, slot blot analyses were used. Both Tom20
and MDH mRNA levels in patient cells were not
signi¢cantly di¡erent from the levels observed in
the control (Fig. 3). Interestingly, mtHSP70 mRNA
Fig. 1. Expression and import of MDH. (A) Western blot analysis of MDH. Total protein (40 Wg) was separated using SDS^PAGE
and transferred to a nitrocellulose membrane. The membrane was treated as described in Section 2. Blots were visualized using the
ECL system. Lane 1, patient; lane 2, control #1; lane 3, control #2. (B) Immunoprecipitation of MDH. C2C12 myoblasts were la-
beled with 100 WCi [35S]methionine for 1 h. Fibroblasts from patient and control cells were labeled with 250 WCi of [35S]methionine
for 6 h. MDH was immunoprecipitated using the MDH polyclonal antibody followed by electronic autoradiography. Lane 1, patient;
lane 2, control #2.
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was 51% higher in patient cells, compared to control
values. When compared to protein levels of expres-
sion, these data suggest the presence of a translation
defect in the patient cells. This was con¢rmed by
measurements of [35S]methionine incorporation into
protein. Rates of incorporation were linear over time
up to 180 min in both patient and control cells (Fig.
4). However, the incorporation of [35S]methionine
was reduced in the patient cells by approximately
50% compared to control cells. This persistent de-
pression in the rate of protein synthesis likely leads
to selective reductions in the steady state levels of
speci¢c proteins, as noted by Western blot analyses
(above).
Analysis of the enzyme activity of respiratory
chain complex IV, cytochrome c oxidase (COX), re-
Fig. 3. Analysis of MDH, Tom20, and mtHSP70 mRNA. Total RNA was extracted from patient and control ¢broblasts. Samples (20
Wg) were applied to a nylon membrane using slot blot apparatus. Blots were subsequently hybridized with respective 32P-labeled
cDNA probes and visualized using electronic autoradiography. Lane 1, patient; lane 2, control. Right panel : quanti¢cation of the sig-
nal corrected for loading using 18S rRNA.
Fig. 2. Western blots of mitochondrial import machinery components. Total protein (40 Wg) was separated using SDS^PAGE and
transferred to nitrocellulose membranes. The membranes were treated as described in Section 2. Blots were visualized using the ECL
system. Lane 1, patient; lane 2, control #1; lane 3, control #2. Right panel : quanti¢cation of the Western blot signals expressed as a
percent of the average of the two controls.
BBADIS 62058 10-4-02
A.A. Rungi et al. / Biochimica et Biophysica Acta 1586 (2001) 146^154150
vealed a 35% decrease in COX activity of the patient
¢broblasts (16 nmol/min per mg) compared to con-
trol (24.5 nmol/min per mg). Corresponding to this,
whole cell oxygen consumption measurements indi-
cated that the rates within the patient ¢broblasts (136
natoms/mg protein per min) were reduced by ap-
proximately 60% of control values (332 natoms/mg
protein per min).
To determine whether changes in total mtDNA, or
its regulatory transcription factor could be contrib-
uting to the de¢ciencies evident in the patient ¢bro-
blasts, the level of COXII mtDNA and the protein
level of mitochondrial transcription factor A (Tfam)
were measured. COX II mtDNA levels were not dif-
ferent from those found in control cells (Fig. 5A).
However, Western blot analyses of Tfam indicated
that the protein was reduced by 32% in the patient
cells compared to controls (Fig. 5B).
4. Discussion
For the past decade, the study of mitochondrial
disease has experienced tremendous growth, particu-
larly with respect to the role of pathogenic mtDNA
mutations. These discoveries have led to the reclassi-
¢cation of many mitochondrial disorders based on
their genetic origin [18,11]. In many cases, the link
between genetic mutations and clinical manifesta-
tions is extremely unclear. In fact, the same point
mutation may present with a variety of clinical phe-
notypes in di¡erent individuals [19]. These di¡erences
cannot solely be attributed to the polyploidic nature
of mtDNA [20]. Consequently, an understanding of
molecular processes involving gene expression and
regulation in diseased individuals is essential to ex-
plain the vast heterogeneity associated with mito-
chondrial disease. Patients with multiple mitochon-
drial disease can exhibit a decrease in the oxidative
capacity of tissue, as evident here by the reduction in
COX activity and the decline in cellular oxygen con-
sumption of patient ¢broblasts. While these de¢cien-
cies have often been reported in patients with
mtDNA mutations, the origin of the defect in this
patient is presumably related to nuclear DNA since
there was no maternal inheritance, and other nu-
clear-encoded mitochondrial proteins were also par-
tially de¢cient.
In the present study, we examine the possibility
that mitochondrial protein import, an essential step
in determining mitochondrial phenotype, was defec-
tive in a patient with multiple mitochondrial disease.
The machinery responsible for this process is entirely
Fig. 5. MtDNA and Tfam expression. (A) Southern blot. Du-
plicates of patient (segment 1) and control (segment 2, control
#1; segment 3, control #2) total DNA were digested and sepa-
rated on a 1% agarose gel. The DNA was then transferred to a
nylon membrane and incubated with a [32P]COXII-labeled
cDNA probe overnight at 42‡C. 1, patient; 2, control. (B)
Western blots analysis of Tfam. Total protein (40 Wg) was sepa-
rated using SDS^PAGE and transferred to a nitrocellulose
membrane. The membrane was treated as described in Section
2. Blots were visualized using the ECL system. Lane 1, patient;
lane 2, control.
Fig. 4. Total protein synthesis. Patient, control #1, and control
#2 ¢broblasts were labeled with 100 WCi of [35S]methionine for
0, 30, 60, 120 or 180 min. Extracts were treated as described in
Section 2. Radioactivity was measured using a scintillation
counter. Control represents average of controls #1 and #2.
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nuclear-encoded. Previous work has indicated that
mutations or decreased expression of certain proteins
comprising the import machinery can lead to disease
[15,16]. In this case, our immunoprecipitation and
Western blot results indicate that MDH and
HSP60 were imported with equal e⁄ciency into the
mitochondria of both patient and control cells. Co-
incident with these observations is the fact that the
protein expression of the membrane import receptor
Tom20 was not di¡erent between patient and control
cells. In contrast, the protein levels of mtHSP70 and
HSP60 were signi¢cantly reduced in the patient cells.
MtHSP70 serves as an import motor, pulling prepro-
teins from the translocases of the inner membrane
(Tim proteins) into the matrix, while HSP60 is an
intramitochondrial chaperone responsible for re-fold-
ing proteins into their mature form. Our data suggest
that the decreases in mtHSP70 and HSP60 were not
limiting the e⁄ciency of protein import, and they
support recent data suggesting that Tom20 may
play a signi¢cant, potentially limiting role, in the
regulation of this process. We have previously shown
that Tom20 is induced under conditions of thyroid
hormone excess in cardiac cells, coincident with an
increase in protein import into the mitochondria [21].
In skeletal muscle, chronic contractile activity led to
an increase in Tom20 levels which paralleled the ac-
celerated rate of precursor import [22]. Most con-
vincingly, experiments in which Tom20 was over-
expressed using an expression vector, or under-
expressed using antisense oligonucleotides, resulted
in parallel changes in protein import rate [23].
To examine upstream events which may be a¡ect-
ing the expression of Tom20, mtHSP70 and MDH,
steady state mRNA levels were measured. Tom20
mRNA levels were normal in patient cells. Since
Tom20 protein was also una¡ected, this suggests
that Tom20 is regulated transcriptionally. In con-
trast, the unchanged MDH mRNA combined with
a reduced MDH protein indicates that events down-
stream of transcription regulate the expression of this
gene product in the patient. Since the post-transla-
tional process of protein import into the organelle
was una¡ected, this is clearly indicative of a trans-
lation defect in MDH expression in patient cells. A
similar problem likely exists with respect to
mtHSP70 expression. MtHSP70 mRNA was upregu-
lated by 50% in patient cells, yet protein levels were
markedly reduced. An increase in mtHSP70 mRNA
has previously been observed under conditions of
metabolic stress, such as muscle contractile activity
[23]. This apparently futile mRNA induction has also
been observed with Tfam, in which mRNA levels
were upregulated while the protein was decreased
in mtDNA depleted cells [24].
The translation defect alluded to above with re-
spect to the expression of selected proteins was re-
£ected by a 50% reduction in [35S]methionine incor-
poration into protein. However, since individual
protein levels were di¡erentially a¡ected, the e¡ect
cannot be generalized to the synthesis of all proteins.
This indicates that mechanisms speci¢c to each pro-
tein, such as translation e⁄ciency, mRNA stability,
or transcriptional activation are involved.
It is also possible that the reduction in total cellu-
lar protein synthesis may be a secondary event pro-
duced by a limited ATP supply, consequent to the
reduced mitochondrial content. This would occur if
the glycolytic capacity of the cells was limited, and
unable to compensate for the mitochondrial defect.
This appears unlikely since the cells were grown in
media containing high glucose levels (2000 mg/l) and
there is no evidence of widespread necrotic cell death
during the time course of our experiments. Nonethe-
less, if this were the case, a reduction in ATP pro-
duction could lead to diminished rates of protein
synthesis and a further decline in mitochondrial pro-
teins and organelle content. This would re£ect a pro-
gressively worsening (i.e., feed-forward) situation in
the patient cells.
Defects in the mitochondrial protein import ma-
chinery have been shown to result in mtDNA dele-
tions [17]. Since many mitochondrial diseases involve
the deletion of certain mtDNA segments, or the gen-
eral depletion of mtDNA, we investigated mtDNA
integrity by evaluating the expression of COXII
mtDNA. In addition, we measured the protein level
of regulatory transcription factor Tfam. The modest
reduction in Tfam levels in the patient which we
observed in the absence of a concomitant decrease
in mtDNA, suggests that the expression of Tfam was
adequate to maintain patient mtDNA at control lev-
els. This ¢nding appears to di¡er from those of
others reporting the parallel expression of mtDNA
and Tfam levels [24^26]. Nevertheless, in one study
[24], Poulton et al. reported decreases in Tfam with-
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out a reduction in mtDNA in some patients with
mitochondrial disease. This is clearly re£ective of a
di¡erent disease etiology, perhaps a manifestation of
the protein synthesis defect which we have observed.
In summary, the maintained rate of protein import
in patient cells was associated with unchanged levels
of the outer membrane import receptor Tom20, re-
£ecting the central role of Tom20 in regulating the
import process. The reduced oxidative capacity of
the patient ¢broblasts was associated with decreases
in several matrix-localized proteins, including MDH.
This reduction was attributed to a decreased synthe-
sis of MDH, rather than a de¢ciency at the level of
mRNA expression or post-translational protein im-
port. While more patients are required to generalize
these observations, this study provides insight into
an additional molecular mechanism that can be al-
tered in mitochondrial disease.
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